Graseby forecasts lower profits
This article was originally published in Clinica
Problems with Graseby's product monitoring division have prompted the UK group to issue a profit warning. Announcing nine-month results, which saw sales fall 2% against the same period last year, Graseby forecasts that profits could be as low as £6 million for the year.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.